75,501 Shares in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Bought by Ruffer LLP

Ruffer LLP acquired a new stake in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 75,501 shares of the company’s stock, valued at approximately $2,598,000.

A number of other institutional investors also recently made changes to their positions in the business. Pacer Advisors Inc. grew its holdings in Harmony Biosciences by 18.2% in the 4th quarter. Pacer Advisors Inc. now owns 2,279,918 shares of the company’s stock worth $78,452,000 after buying an additional 351,582 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its position in shares of Harmony Biosciences by 27.1% in the third quarter. Massachusetts Financial Services Co. MA now owns 660,391 shares of the company’s stock worth $26,416,000 after purchasing an additional 140,690 shares in the last quarter. HealthInvest Partners AB increased its holdings in Harmony Biosciences by 335.2% in the third quarter. HealthInvest Partners AB now owns 151,875 shares of the company’s stock worth $6,075,000 after buying an additional 116,975 shares during the last quarter. Capital Management Corp VA grew its holdings in Harmony Biosciences by 43.5% in the 4th quarter. Capital Management Corp VA now owns 340,960 shares of the company’s stock valued at $11,732,000 after buying an additional 103,308 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of Harmony Biosciences by 27.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 472,028 shares of the company’s stock worth $16,242,000 after acquiring an additional 100,586 shares during the last quarter. 86.23% of the stock is owned by institutional investors and hedge funds.

Harmony Biosciences Trading Down 0.1 %

Shares of HRMY stock opened at $33.67 on Friday. The company has a current ratio of 3.24, a quick ratio of 3.20 and a debt-to-equity ratio of 0.28. Harmony Biosciences Holdings, Inc. has a 1 year low of $28.14 and a 1 year high of $41.61. The stock has a market cap of $1.93 billion, a P/E ratio of 15.96, a price-to-earnings-growth ratio of 0.47 and a beta of 0.82. The stock has a 50 day simple moving average of $36.51 and a 200 day simple moving average of $35.72.

Harmony Biosciences (NASDAQ:HRMY) last announced its earnings results on Tuesday, February 25th. The company reported $0.85 EPS for the quarter, topping the consensus estimate of $0.74 by $0.11. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. The firm had revenue of $201.30 million for the quarter, compared to the consensus estimate of $201.25 million. During the same period in the previous year, the business earned $0.45 EPS. The business’s quarterly revenue was up 19.5% compared to the same quarter last year. On average, research analysts predict that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have weighed in on HRMY. Needham & Company LLC reissued a “buy” rating and issued a $50.00 price target on shares of Harmony Biosciences in a report on Tuesday, February 25th. Deutsche Bank Aktiengesellschaft started coverage on Harmony Biosciences in a research note on Tuesday, February 11th. They set a “buy” rating and a $55.00 price target on the stock. HC Wainwright decreased their price objective on Harmony Biosciences from $75.00 to $70.00 and set a “buy” rating on the stock in a report on Thursday, February 27th. Finally, Mizuho decreased their target price on shares of Harmony Biosciences from $52.00 to $42.00 and set an “outperform” rating on the stock in a research report on Thursday, February 20th. Nine research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $53.11.

Insider Activity at Harmony Biosciences

In related news, CEO Jeffrey M. Dayno sold 19,293 shares of the stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $40.13, for a total value of $774,228.09. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Sandip Kapadia sold 25,000 shares of the firm’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $40.18, for a total value of $1,004,500.00. The disclosure for this sale can be found here. Insiders have sold 72,452 shares of company stock worth $2,831,679 in the last quarter. Company insiders own 30.80% of the company’s stock.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.